Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Royal Bank of Canada — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.98 (market cap $29.60B), while Royal Bank of Canada trades at $210.44 (market cap $292.32B). The key difference: Royal Bank of Canada is far larger — about 9.9× Alnylam Pharmaceuticals, Inc.'s market cap, and Royal Bank of Canada pays a 2.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RY | |
|---|---|---|
Market Cap | $29.60B | $292.32B |
Sector | Health | Financials |
52-Week High | $491.22 | $217.87 |
52-Week Low | $205.48 | $134.80 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 2.37% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
